TY - BOOK AU - Bhoite, Rahul R AU - Kanwal, Arjun AU - Suman, Annya AU - Young, Raymond K TI - Anticoagulation in Pulmonary Arterial Hypertension: Do We Know the Answer?. [Review] SN - 0146-2806 PY - 2021/// KW - *Anticoagulants KW - *Hypertension, Pulmonary KW - *Pulmonary Arterial Hypertension KW - *Thrombosis KW - Anticoagulants/tu [Therapeutic Use] KW - Humans KW - Hypertension, Pulmonary/dt [Drug Therapy] KW - Pulmonary Arterial Hypertension/dt [Drug Therapy] KW - Pulmonary Artery KW - Randomized Controlled Trials as Topic KW - Thrombosis/dt [Drug Therapy] KW - MedStar Union Memorial Hospital KW - Medicine KW - MedStar Health Baltimore Residents KW - Journal Article KW - Review N1 - Available online from MWHC library: 1995 - 2009, Available in print through MWHC library:1999-2007 N2 - The shear stress and hypoxia in the pulmonary artery in patients with pulmonary arterial hypertension(PAH) causes endothelial dysfunction, smooth muscle proliferation and activation of thrombotic pathways leading to in situ thrombosis. Targeting the thrombotic pathways is a proposed mechanism to slow disease progression and improve survival. Over the years, the survival in patients with PAH has improved due to multiple factors with the increased use of anticoagulation as one of them. Both European Respiratory Society/European Society of Cardiology and American College of Cardiology/American Heart Association guidelines make grade II recommendations for using anticoagulation in PAH. The guidelines are based on weak observational studies with high risk of bias which have only studied warfarin as the choice of anticoagulation. In this article, we review the pathophysiology, rationale and the current literature investigating the role of anticoagulation in PAH. Copyright (c) 2020 Elsevier Inc. All rights reserved UR - https://dx.doi.org/10.1016/j.cpcardiol.2020.100738 ER -